GLP-1 for Men: Weight Loss, Muscle, and Testosterone

*This article is for informational purposes only. It is not medical advice. Consult a licensed healthcare provider before starting any medication or treatment program.*

---

If you've been doing research on GLP-1 medications, you may have noticed something: most of the content is written with women in mind. The before-and-afters, the anecdotes, the framing around hormones and body image. Men are there in the clinical data, but they are rarely centered in the conversation.

That is a gap worth closing.

GLP-1 medications like semaglutide and tirzepatide work for men. The clinical evidence is clear on this. But there are some real, physiology-driven differences in how men experience weight loss on these medications, what concerns are actually worth thinking about, and what the research shows about less-discussed topics like testosterone and muscle mass.

This article covers all of it, with evidence behind every claim.

---

How Men Carry Weight Differently

Before getting into the medications themselves, it helps to understand what makes male body fat distinct.

Men tend to accumulate visceral fat, the deep abdominal fat that wraps around organs. This fat type is metabolically active in the worst way: it drives insulin resistance, inflammation, and cardiovascular risk more aggressively than subcutaneous fat (the kind you can pinch under the skin). Women, especially before menopause, are more likely to store fat in the hips and thighs, which is metabolically less dangerous.

This pattern has a clinical upside for men on GLP-1 therapy. Visceral fat is more metabolically responsive than subcutaneous fat, meaning it tends to shrink faster during weight loss interventions. Men starting GLP-1 treatment often see meaningful changes in waist circumference and abdominal fullness relatively early in the treatment course.

---

What the Clinical Trials Show

The two landmark trials that established GLP-1 medications as serious weight-loss tools included significant numbers of men.

STEP 1 (semaglutide): The STEP 1 trial, published in the *New England Journal of Medicine* in 2021, showed that once-weekly semaglutide 2.4mg produced an average body weight reduction of 14.9% over 68 weeks in adults with obesity or overweight and at least one weight-related condition.[^1] The trial included both men and women.

SURMOUNT-1 (tirzepatide): The SURMOUNT-1 trial, published in 2022, showed tirzepatide at its highest dose (15mg weekly) produced an average weight reduction of 20.9% over 72 weeks in adults with obesity.[^2] Men and women were both well-represented.

SELECT trial cardiovascular outcomes: The SELECT trial, published in *NEJM* in 2023, is particularly relevant for men. The trial enrolled 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes. Approximately 72% of participants were men. Semaglutide reduced the risk of major cardiovascular events by 20% compared to placebo.[^3] For men in their 40s and 50s who carry both excess weight and cardiovascular risk, this is a meaningful finding beyond the scale number.

A 2026 systematic review and meta-analysis in *JAMA Internal Medicine* examined heterogeneity of GLP-1 treatment effects across patient subgroups. The analysis found that while both sexes respond to GLP-1 therapy, the magnitude of response varies and sex may be one factor influencing outcomes.[^4] This underscores why understanding the male-specific picture matters.

---

The Muscle Mass Question

This is the concern men ask about most, and it deserves a direct answer.

When you lose weight quickly, some of what you lose is lean mass, not just fat. This is true regardless of the method: caloric restriction, surgery, or medication. A 2026 systematic review in *Annals of Internal Medicine* found that roughly 35% of the weight lost during GLP-1 treatment is lean mass.[^5] For a man who loses 30 pounds, that could mean around 10 pounds of that is muscle.

That figure sounds alarming out of context. A few important points:

The absolute lean mass loss matters, not just the percentage. Men typically carry more baseline muscle mass than women. Losing some lean mass while significantly reducing visceral fat and total body fat can still improve metabolic health and functional capacity.

Resistance training changes the equation. A 2024 review in *Diabetes Care* found that combining GLP-1 pharmacotherapy with resistance exercise can preserve lean mass during treatment.[^6] Lifting weights signals your body to protect muscle even during a caloric deficit. This is one of the most practical things men on GLP-1 therapy can do.

For a deeper breakdown of the lean mass evidence and practical strategies, see Prescriva's guide to [semaglutide and muscle loss](/resources/semaglutide-muscle-loss-lean-mass).

<InlineImage src="/images/articles/muscle-preservation-glp1-hero.jpg" alt="Man doing resistance training at a gym, maintaining muscle while on GLP-1 treatment" caption="Resistance training is the most evidence-supported way to protect lean mass during GLP-1 treatment." />

---

GLP-1 and Testosterone: What the Research Actually Shows

Many men with obesity also have low testosterone. This relationship is not coincidental.

Adipose (fat) tissue, especially visceral fat, contains high levels of an enzyme called aromatase. Aromatase converts testosterone into estrogen. The more visceral fat a man carries, the more of his testosterone gets converted, and the lower his free testosterone tends to run. A 2014 study in *Hormone and Metabolic Research* showed that caloric restriction and weight loss directly increases serum testosterone in obese men through this mechanism.[^7]

This means weight loss itself, by any method, tends to improve testosterone levels in men with obesity-related low testosterone.

Two recent reviews have looked specifically at what GLP-1 medications do to male hormones:

A 2026 systematic review in the *Journal of Sexual Medicine* examined the effects of GLP-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes. The review found that GLP-1 therapy was associated with improvements in testosterone levels alongside weight and metabolic improvements.[^8]

A 2025 review in *The Aging Male*, co-authored by endocrinologist Michael Zitzmann, examined how GLP-1 receptor agonists, lifestyle modification, and testosterone intersect in obese men with hypogonadism. The authors concluded that GLP-1-driven weight loss can meaningfully improve testosterone levels in men with obesity-related hormonal suppression.[^9]

An important caveat: not all low testosterone is caused by obesity. Hypogonadism has multiple causes. GLP-1 therapy can improve testosterone when excess adiposity is the primary driver, but it is not a testosterone treatment. If you have concerns about testosterone, a healthcare provider can evaluate the full picture with lab work.

---

Side Effects: Are There Differences for Men?

The core side effect profile of GLP-1 medications is consistent across sexes: nausea, constipation, decreased appetite, and occasional vomiting, especially during dose escalation. These effects are driven by how the medication slows gastric emptying and acts on appetite centers in the brain.

The 2026 analysis in *JAMA Internal Medicine* found no dramatic sex-based differences in GLP-1 side effect rates at the population level, though individual variation is common.[^4]

Beyond the common GI effects, GLP-1 receptor agonists carry rarer but more serious risks worth knowing about, including pancreatitis, gallbladder disease, and acute kidney injury (often secondary to dehydration from vomiting). These are uncommon but warrant prompt medical attention if symptoms develop. Your prescribing provider will review your full medical history and discuss the complete risk profile before treatment.

A few practical notes for men:

Nausea tends to peak during the first 4 to 8 weeks, then improve as your body adjusts to the medication. Eating smaller, lower-fat meals during this period helps. High-fat and highly processed foods seem to worsen nausea for most people early on.

Decreased appetite is pronounced, and for many men this is the most welcome effect. For men who have spent years fighting strong food cravings, the reduction in what is sometimes called "food noise" can feel significant.

---

Getting a Prescription: What Men Need to Know

GLP-1 medications for weight management generally require meeting at least one of these criteria:

• A BMI of 30 or higher
• A BMI of 27 or higher with at least one weight-related health condition (such as hypertension, prediabetes, high cholesterol, or sleep apnea)

Men are often underrepresented in weight-loss telehealth programs, partly because many of the marketing messages have historically skewed toward women. But the qualification criteria are the same, and telehealth platforms make the process straightforward.

Through Prescriva, you can have an online visit with a licensed provider, review your health history, and, if clinically appropriate, receive a prescription for a compounded GLP-1 medication. The process takes place from home, without waiting rooms or in-person visits.

For more detail on who qualifies, see our guide to [GLP-1 eligibility criteria](/resources/who-qualifies-for-glp1-medications).

Important: Compounded semaglutide and tirzepatide are not FDA-approved drugs. They are prepared by licensed compounding pharmacies under FDA oversight. This is not the same as the FDA-approved brand-name medications (Wegovy, Ozempic, Zepbound). Your provider will review whether compounded GLP-1 treatment is appropriate for your individual situation.

Contraindications. GLP-1 receptor agonists carry an FDA boxed warning based on rodent studies showing dose-dependent thyroid C-cell tumors. Semaglutide and tirzepatide are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). A history of pancreatitis or severe gastrointestinal disease also warrants careful clinical evaluation. Be sure to disclose your full medical and family history during your provider visit.

---

Exercise While on GLP-1 Treatment

If you are serious about preserving muscle and getting the most out of your GLP-1 treatment, resistance training deserves a place in your weekly routine. Two to three sessions per week of progressive strength training is a well-supported target.

Cardiovascular exercise still matters for heart health and metabolic fitness, but it does not protect lean mass the way resistance training does. Combining both provides the broadest set of benefits.

For a detailed guide to exercising on GLP-1 medications, including what to expect as your appetite and energy levels shift, see Prescriva's [exercise guide for GLP-1 patients](/resources/exercise-on-glp1-medications).

---

Cost and Access

Compounded semaglutide and tirzepatide are typically more affordable than brand-name GLP-1 medications, which can run over $1,000 per month without insurance coverage. Compounded options range widely in price depending on the program and dose. Prescriva pricing includes the provider consultation, medication, and shipping. You can cancel anytime.

For a current breakdown of compounded GLP-1 pricing and what to expect, see the [2026 cost guide](/resources/compounded-semaglutide-cost-2026).

---

The Bottom Line

GLP-1 medications are effective for men. The clinical trials are clear, and the biology supports why men, particularly those with high visceral fat and obesity-related low testosterone, may be well-positioned to benefit.

The differences worth knowing: men tend to lose more visceral fat early, lean mass loss is real but manageable with resistance training, and weight loss through GLP-1 therapy can improve testosterone in men where obesity is suppressing it.

If you are a man considering GLP-1 treatment, the conversation starts with a simple clinical evaluation. Prescriva's licensed providers can help you understand whether you qualify and what a treatment plan might look like for your specific situation.

---

*Compounded semaglutide and tirzepatide are not FDA-approved medications. Results vary. This content is not medical advice. Consult a licensed healthcare provider.*

---

References

[^1]: Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med.* 2021;384(11):989-1002. PMID: 33567185.

[^2]: Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med.* 2022;387(3):205-216. PMID: 35658024.

[^3]: Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med.* 2023;389(24):2221-2232. PMID: 37952131.

[^4]: Alexander GC, Xiao X, Dilek S, et al. Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis. *JAMA Intern Med.* 2026 Mar 2. PMID: 41770554.

[^5]: Batsis JA, Gavras A, Gross DC, et al. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review. *Ann Intern Med.* 2026 Apr 17. PMID: 41996180.

[^6]: Locatelli JC, Costa JG, Haynes A, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? *Diabetes Care.* 2024;47(10). PMID: 38687506.

[^7]: Schulte DM, Hahn M, Oberhäuser F, et al. Caloric restriction increases serum testosterone concentrations in obese male subjects by two distinct mechanisms. *Horm Metab Res.* 2014;46(4):283-286. PMID: 24198220.

[^8]: Deameh MG, Ramez M, Rowaiee R, et al. Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review. *J Sex Med.* 2026 Jan 7. PMID: 41498523.

[^9]: Antonič KG, Zitzmann M. The male hormone reset: how GLP-1RAs, lifestyle and testosterone transform obesity-linked problems. *Aging Male.* 2025;28(1). PMID: 41399135.